Start typing to retrieve search suggestions. When suggestions are available use up and down arrows to review and ENTER to select. Continue typing to refine.
Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

Nuvaxovid JN.1 PFS dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) {equilateral_black_triangle}

Active Ingredient:
SARS-CoV-2 recombinant spike protein
Company:  
Novavax, Inc See contact details
ATC code: 
J07BN04
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL)
{arrow_left}
{arrow_right}
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine.
{info_black}
Last updated on emc: 09 Sep 2025

{equilateral_black_triangle} This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

{pdf} View or print the patient leaflet as PDF
Novavax, Inc
Company image
Address
21 Firstfield Road, Gaithersburg, Maryland, 20878, USA
Telephone
+1 240-268-2000
Fax
+1 240-268-2100
Medical Information Direct Line
+44 020 3514 1838
Medical Information Website
novavaxmedinfo.com
Customer Care direct line
+44 020 3514 1838
WWW
www.Novavax.com
WWW
www.novavaxcovidvaccine.com